Table 3.

Relation between clinicopathologic data and PCDH20 promoter hypermethylation

nPCDH20 hypermethylation *P
Total5
Gender
    Male3923 (59.0%)0.4541
    Female209 (45.0%)
Age (y)
    Median72.5>0.9999
    >654524 (53.3%)
    ≤65148 (57.1%)
Histologic subtype
    Adenocarcinoma3821 (55.3%)0.3562
    Squamous cell carcinoma199 (47.4%)
    Large cell carcinoma22 (100%)
Differentiation
    Well-moderate4524 (53.3%)>0.9999
    Poor148 (57.1%)
Smoking habits
    Smoker4024 (60.0%)0.3105
    Nonsmoker198 (42.1%)
Tumor-node-metastasis classification
T stage
    T1199 (47.4%)0.6491
    T2-T44023 (57.5%)
N stage
    N04324 (55.8%)0.9127
    N1-N2168 (50%)
M stage
    M05832 (55.2%)ND
    M110 (0%)
Stage
    I3920 (51.3%)0.7125
    II-IV2012 (60%)
  • Abbreviation: ND, not determined.

  • * Methylation status was determined by MSP as described in Materials and Methods.

  • P values are from χ2 or Fisher's exact test and were statistically significant when <0.05 (two-sided).